Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Other financing activities (2020 - 2022)

Avidity Biosciences (RNA) has disclosed Other financing activities for 3 consecutive years, with -$745000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Other financing activities fell 7550.0% year-over-year to -$745000.0, compared with a TTM value of $17.0 million through Sep 2022, down 29.53%, and an annual FY2021 reading of $17.1 million, down 29.01% over the prior year.
  • Other financing activities was -$745000.0 for Q2 2022 at Avidity Biosciences, down from $745000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $24.0 million in Q4 2020 and bottomed at -$22.7 million in Q3 2020.
  • Average Other financing activities over 3 years is $4.6 million, with a median of $193000.0 recorded in 2020.
  • The sharpest move saw Other financing activities soared 100.28% in 2021, then tumbled 7550.0% in 2022.
  • Year by year, Other financing activities stood at $24.0 million in 2020, then fell by 29.31% to $17.0 million in 2021, then tumbled by 104.39% to -$745000.0 in 2022.
  • Business Quant data shows Other financing activities for RNA at -$745000.0 in Q2 2022, $745000.0 in Q1 2022, and $17.0 million in Q4 2021.